Research programme: nucleoside hepatitis C virus NS5B polymerase inhibitors - Genelabs

Drug Profile

Research programme: nucleoside hepatitis C virus NS5B polymerase inhibitors - Genelabs

Alternative Names: HCV inhibitors - Genelabs/Gilead; Nucleoside HCV NS5b polymerase inhibitors - Genelabs/Gilead

Latest Information Update: 14 Jul 2010

Price : $50

At a glance

  • Originator Genelabs Technologies
  • Class Nucleosides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 14 Jul 2010 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
  • 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
  • 24 Jun 2008 Gilead Sciences terminates its involvement in this collaboration and returns all rights to compound arising from this programme to Genelabs Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top